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Abstract 
This research examines the timeline of the discovery and research of Primary Open-Angle Glaucoma (POAG). 
By reviewing the literature on genetic and molecular mechanisms, we aim to emphasize a long-term treatment 
solution (iSTENT) to mitigate intraocular pressure (IOP) related to POAG etiology and disease progression. 
POAG is a multifactorial, autosomal dominant, adult-onset eye disease wherein the optic nerve cells become 
damaged due to a buildup of excess aqueous humor, resulting in increased IOP. Consequently, POAG leads to 
progressive loss of peripheral vision and is the leading cause of blindness in the US. Due to the multifactorial 
nature of glaucoma’s inheritance pattern and disease pathology, over 20 disease-associated loci have been 
implicated with POAG and its mechanisms remain relatively obscure. POAG remains a hotbed for 
multifactorial genetic research and the relationships between heterogeneity and environmental/genetic factors. 
To develop a more permanent solution for Glaucoma, we highlight a surgical insertion of a stent in the 
trabecular meshwork providing long-lasting dilation to the blocked drainage channels implicated with increased 
IOP and POAG progression. This procedure would allow for aqueous humor outflow from the eye and 
subsequent reduction of pressure-induced retinal ganglion cell damage. POAG’s progressive loss of vision due 
to polygenic inheritance and environmental factors is currently experienced by over 2.25 million Americans and 
will continue to grow as POAG-associated genes are maintained in subsequent generations. Therefore, a 
complete understanding of the history, etiology, and genetic mechanisms is critical for the development of 
effective and long-lasting treatment options. 
 
Keywords: genetics, multifactorial disease, MYOC (gene), intraocular pressure (IOP), blindness, iSent Medical 
Device 
 
In a healthy eye, fluid called aqueous humor is 
secreted into the posterior chamber (behind the iris) via 
the ciliary processes attached to the ciliary body. The 
aqueous humor then crosses the pupil to provide 
nutrients to the cornea (clear portion) in the anterior 
chamber (in front of the iris) of the eye (Llobet et al., 
2003). Lastly, the eye fluid exits the anterior chamber 
through the trabecular meshwork tissue (TM) and 
subsequently through Schlemm’s canal (See Figure 1 
for anatomy of the eye). 
In contrast, Primary Open-Angle Glaucoma 
(POAG) is an adult-onset eye disease that causes 
progressive blindness, typically beginning with a 
gradual loss of peripheral vision. This disease is often 
a result of defects in the trabecular meshwork 
preventing aqueous humor from properly exiting the 
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eye cavity through drainage channels. This inability of 
the aqueous humor to drain properly causes a build-up 
in intraocular pressure (IOP), referring to fluid pressure 
within the eye. As IOP increases due to blocked or 
collapsed drainage channels in the trabecular 
meshwork, retinal ganglion cells (optic nerve cells) 
become severely damaged or undergo apoptosis (cell 
death) resulting in the permanent progressive loss of 
vision (See Figure 2 for an illustration of the 
development of glaucoma). The “Open-Angle” portion 
of the POAG name refers to the presence of space 
between the iris and cornea.  
From a genetic perspective, POAG is a 
multifactorial disease with complex inheritance 
meaning that multiple genes have been known to cause 
or affect the expression of the disease. Additionally, 
the penetrance and expressivity of POAG can vary 
drastically from patient to patient (Gemenetzi et al., 
2012). In other words, people who carry the POAG 
mutations may or may not exhibit signs and symptoms 
of the disease. Genetic and environmental modifiers of 
POAG interact to contribute to the notable complexity 
of its disease etiology, severity, and inheritance 
patterns. Some of the most common non-genetic 
modifiers include race, untreated high blood pressure, 
cigarette smoking, family history of glaucoma, 
diabetes, and being nearsighted. Currently, there is no 
permanent cure for POAG and current treatment 
options require daily use of specialized IOP reducing 
eye drops or multiple follow-up procedures. Thus, 
using current and historical research, we investigate a 
molecular mechanism of POAG to emphasize a 
permanent treatment solution to IOP-induced retinal 
ganglion cell injury/death using an in-development 




400 BCE Hippocrates 
Taking a look at the history, Glaucoma has 
been prevalent in the human population dating back to 
400BCE where it was mentioned by Hippocrates, the 
Father of Modern Medicine. He referred to this 
condition as  “Glaykoseis” - blindness that occurs in 
the elderly (Leffler, 2015).  
502-575 CE Aetius of Amida 
By 500CE a Byzantine physician, Amida, 
grouped it under the term “Amaurosis”, a 
categorization used to describe eye diseases that caused 
severe vision impairment as a result of increased eye 
pressure on the optic nerve in patients with eyes that 
appeared normal (Leffler, 2015).  
1101-1300 Benevenutus Grassus 
12th-century optometrist Benevenutus Grassus 
coined the term “gutta serena” to describe incurable 
blindness caused by an obstructed optic nerve (Leffler, 
2015).  
1850 Invention of Ophthalmoscope 
In the 1850s a breakthrough in diagnosis 
occurred with the invention of the ophthalmoscope. 
For the first time in history, this revolutionary device 
allowed physicians to visually identify a degraded 
optic nerve and finally led to the inception of the 
current name “Glaucoma” (Leffler, 2015). 
1856 Albrecht von Graefe 
Albrecht von Graefe introduced iridectomy as 
one of the earliest forms of glaucoma treatment. This 
operation involves surgical removal of a segment of the 
iris allowing for drainage of excess fluid from the eye. 
Graefe then went on to invent the tonometer, a tool 
currently used to measure the eye pressure of glaucoma 
patients. Graefe is also credited with the 
implementation of visual field testing, a commonly 
used practice used to identify and diagnose glaucoma 
(Leffler, 2015).  
1960 Trabeculectomy Introduced 
In 1960 Trabeculectomy, a procedure that 
involves surgical removal of a small portion of the 
trabecular meshwork to drain aqueous humor was 
introduced. This procedure shifted several future 
procedures towards the trabecular meshwork and its 
drainage channels as a new, more efficient target for 
surgical intervention (Razeghinejad, 2011). 
1967 Discovery of Multifactorial Disease Etiology 
The study by Mansour, F. P., described 
POAG’s locus heterogeneity by performing parent-
offspring transmission comparisons (i.e. pedigree). 
This study further concluded polygenic inheritance in 
POAG, with variable age of onset and expressivity. 
This discovery confirmed that multiple genes along 
with environmental factors all played a collective role 
in disease manifestation and severity (Armaly, 2017).  
1996 Prostaglandin Medications Introduced 
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First eye drops that reduce intraocular pressure 
are introduced and are still currently the first line of 
medical therapy for glaucoma. Prostaglandins act by 
activating receptors that can trigger a restructuring of 
the extracellular matrix to allow for aqueous outflow 
(Fingeret, 2001). 
1997 Discovery of First Disease-Associated Gene 
MYOC 
A study by Stone et al performed Sequence-
Tagged Sites (STS) on candidate genes based on 
affected familial association studies of POAG. 
Radiation hybrid gene mapping was used to suggest the 
presence of the MYOC disease-associated gene near 
the candidate gene markers (Stone et al., 1997). 
1997 Laser Trabeculoplasty Introduced 
Laser-based surgery, in which a laser is used to 
cut damaged regions of the trabecular meshwork, 
begins being practiced by optometrists. This procedure 
currently remains the most frequently used glaucoma 
treatment (Razeghinejad, 2011). 
Current Research: 
2009 Identification of 3 susceptible Loci in Japanese 
Populations 
3 susceptible loci on chromosomes 1, 10, and 
12 were identified using a genome-wide SNP 
association study of 418 POAG patients. Glaucoma 
was found to exhibit familial aggregation (autosomal 
dominant; ~50% inheritance), with variable penetrance 
& expressivity amongst individuals and various ethnic 
groups (African Americans, Japanese and Northern 
Europeans) (Nakano et al., 2009).   
2009 Investigation of MYOC Hotspots on Glaucoma 
Etiology 
This 2009 research found several POAG-
associated mutations are often a result of Single 
Nucleotide Polymorphisms (SNPs). The MYOC gene 
which encodes the protein myocilin, produced in the 
trabecular meshwork tissue, was discovered to be a key 
hotspot in Glaucoma etiology.  
 The exact function of myocilin is unknown. 
However, various mutations of MYOC have been 
associated with retinal ganglion damage and death. 
This study indicated that the MYOC gene segment, in 
particular, accrues several point mutations. These point 
mutations occur most commonly as a result of 
spontaneous or mutagen-induced DNA damage, 
causing errors in DNA replication/repair by DNA 
polymerase (Kwon et al., 2009).  
2013 Research Implicates Dual Leucine Zipper Kinase 
as a Key Mediator of Retinal Ganglion Cell Apoptosis 
A 2013 Research identified several important 
myocilin domains and some of their normal roles. 
From the illustrations above, dual Leucine zipper 
kinase in the N-terminus was discovered to be a highly 
important signaling component during axonal damage 
& retinal ganglion cell death, while the C-terminal 
domains in myocilin functioned to direct proteins to 
peroxisomes for oxidation reactions (Welsbie et al., 
2013). 
2013 Research Implicates Dual Leucine Zipper Kinase 
as a Key Mediator of Retinal Ganglion Cell Apoptosis 
A 2013 Research identified several important 
myocilin domains and some of their normal roles. 
From the illustrations above, dual Leucine zipper 
kinase in the N-terminus was discovered to be a highly 
important signaling component during axonal damage 
& retinal ganglion cell death, while the C-terminal 
domains in myocilin functioned to direct proteins to 
peroxisomes for oxidation reactions (Welsbie et al., 
2013). 
2015 Psychosocial Study on Glaucoma-Associated 
Visual Acuity & Field Loss 
This study found that glaucoma-related loss of 
visual acuity and field had significant psychosocial 
effects on the patients. This was determined using a 
quality of life questionnaire of 192 patients. Results 
indicated that glaucoma patients had 63% greater 
anxiety, 71% lower self-image, 38% less psychological 
well-being & 32.4% reduced confidence in health care 
compared to negative controls (Chan et al., 2015). 
2017 Genome-wide Association Identifies 16 total 
POAG-associated Gene Loci 
Genome-wide association studies for different 
types of adult-onset glaucoma have identified 16 total 
POAG-associated loci involved in a variety of 
important biological functions including; cytokine 
signaling, lipid metabolism, membrane biology, and 
ocular development.  
 This discovery truly emphasizes the complex, 
multifactorial nature of this disease. Several of these 
seemingly unrelated genetic loci could be acting 
together or independently to reduce or exacerbate the 
condition of this glaucoma. This relative abundance of 
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genetic modifiers coupled with environmental factors 
contributes to the notable heterogeneity of glaucoma 
manifestation (multifactorial) (Bailey et al., 2016). 
Potential Long-Term Treatment (iStent): Due to the 
complex, multifactorial nature of glaucoma, genetic 
intervention and long-term IOP reducing therapy may 
present significantly challenging biological/financial 
barriers (Wiggs et al., 2017). Therefore, consideration 
of more permanent solutions such as the iStent or other 
stent-based procedures could provide efficient 
protection against progressive loss of vision and offer 
additional long-term health and financial benefits.  
Surgical insertion of the iStent® (stent) into the 
trabecular meshwork allows aqueous humor to drain 
freely into the Schlemm’s canal from the anterior 
chamber, reducing IOP-induced retinal ganglion cell 
damage and death (Resende et al., 2016). This 
procedure is known as minimally invasive glaucoma 
surgery (MIGS) has shown notably low complication 
rates and long-term reduction in unmedicated IOP.  
A 13-month follow-up of 39 POAG patients 
treated with the insertion of 2 iStents has exhibited a 
mean unmedicated IOP reduction of 25.3 ± 1.8 mmHg 
preoperatively to 17.1 ± 2.2 mmHg (32.4%) (Resende 
et al., 2016). Due to the notable heterogeneity of 
glaucoma, it is an important model for the study of 
multifactorial disease etiology. 
 
Discussion 
POAG’s incurable progressive loss of vision is 
currently experienced by over 2.25 million Americans 
and remains the leading cause of blindness in the US. 
With a long history of prevalence in individuals dating 
back to as early as 400 BCE (Leffler, 2015), this 
disease possesses multifactorial characteristics 
contributing to the complexity of this disease's 
penetrance, expressivity, and overall inheritance 
patterns. 
POAG’s influence from both genetic and 
environmental modifiers also diminishes the accurate 
evaluation of POAG prognosis. Patients typically 
exhibit varying severity of symptoms with individuals 
who may even be completely unaware of their 
condition due to its often gradual progression. 
Furthermore, the incurable progressive blindness due 
to POAG has also been shown to additionally cause a 
decline in the mental state of the patients, highlighting 
several of the long-term, non-physical implications of 
this disease (Zhou et al., 2016). 
 Current research has also identified several of 
the proteinaceous, structural defects of POAG-
implicated gene products such as Myocilin from the 
MYOC gene. Discovery and analysis of such defective 
conformational structures of POAG-associated 
proteins may unlock breakthrough permanent 
treatment avenues (Welsbie et al., 2013). With the 
introduction of the iStent medical device, we believe 
this device along with other similar stent-based devices 
could provide long-term financial and clinical benefits. 
The iStent in particular is promising as it bypasses the 
genetic aspects of POAG and intervenes at the physical 
level (direct insertion into the eye) with little to no 
follow-ups (Resende et al., 2016).  
 A comprehensive understanding of POAG’s 
unique genetic characteristics, history, molecular 
mechanisms, and current research may provide key 
insight to a cure for IOP-induced retinal ganglion cell 
damage. Furthermore, because POAG remains so 
prevalent in the United States, a complete 
understanding of its history and etiology is crucial for 
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Appendix A: Figure 1. Anatomy of a healthy eye 
 
 
Note. In this figure, the normal cycle of aqueous humor throughout the eye is depicted. Starting from the ciliary 
processes and ending at Schlemm’s canal (black arrows). From “Schematic Diagram of the Aqueous Humor 
Cycle” by Artur Llobet, Xavier Gaull, and Arcadi Gual licensed under CC BY 2.0. 
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Appendix B: Figure 2. Development of Glaucoma 
  
Note. This figure compares the flow of aqueous humor in a normal eye versus in an eye that develops Glaucoma 
due to blockage of the trabecular meshwork tissue and subsequent increase of IOP. From “Development of 
Glaucoma” by Alila Medical Media licensed under CC BY 2.0. 
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Appendix C: Figure 3. POAG mechanism associated with the MYOC gene hotspot 
 
 
Note. Figure 3.1. Increasing IOP results in radial & posterior distorting forces within the eye. Increased pressure 
induces apoptosis/damage retinal ganglion cells & distort vision. Figure 3.2. The iris lies closer to the lens, 
exhibiting the characteristic, “open-angle” between the iris & cornea (left). The presence of a “closed-angle”, 
indicates the ciliary body & iris’ proximity to the cornea (right). In both diagrams, the trabecular meshwork is 
non-functioning or damaged in Glaucoma, preventing the efficient drainage of aqueous humor. Figure 3.3. 
Illustration of a point mutation on Exon 3-MYOC (gene implicated in POAG), resulting in a proline to a leucine 
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Appendix D: Figure 4. Illustration of iStent function 
 
 
Note. Left panel: Dysfunctional trabecular meshwork causes a build-up of aqueous humor. Right panel: 
Installation of the iStent allows aqueous humor to properly drain; decreasing IOP. 
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Appendix E: Figure 5. iStent anatomy 
 
Note. The iStent anatomy allows for short & permanent procedures. Beginning with insertion using a needlepoint 
self-trephining tip, retention arches secure the device in position, and allows aqueous humor to freely drain 
through the trabecular meshwork (right). From “iStent Anatomy” by The Eye Institute licensed under CC BY 2.0. 
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Appendix F: Figure 6. iStent(s) in the trabecular meshwork 
 
Note. Left panel: Image of direct ophthalmoscopy of the eye. Right panel: iStent(s) are installed within the 
trabecular meshwork which appears like white circles between the upper translucent layer (cornea) and lower 
beige layer (iris, ciliary body). From “Direct Gonioscopy and 2 Inserted iStents Under Gonioscopy” by Journal 
of Ophthalmology licensed under CC BY 2.0. 
 
